share_log

新銳醫藥：截至2024年3月31日之股份發行人的證券變動月報表

NEW RAY MEDIC: MONTHLY RETURN OF EQUITY ISSUER ON MOVEMENTS IN SECURITIES FOR THE MONTH ENDED 31 MARCH 2024

香港交易所 ·  Apr 2 05:10
Summary by Moomoo AI
新銳醫藥國際控股有限公司（新銳醫藥）於2024年4月2日向香港交易及結算所有限公司提交了最新的證券變動月報表，報告截至2024年3月31日的公司股份變動情況。報告顯示，新銳醫藥的法定/註冊股本及已發行股份在報告期內均無變動，維持在3,000,000,000股，每股面值0.05港元，總股本為150,000,000港元。此外，根據2013年10月25日採納的股份期權計劃，公司於報告月內無新增股份期權行使，結存的股份期權數目為143,200,000，並無因行使期權而得到的資金。公司秘書吳日升確認，所有證券發行均已獲得董事會批准，並符合香港聯合交易所有限公司證券上市規則的相關要求。
新銳醫藥國際控股有限公司（新銳醫藥）於2024年4月2日向香港交易及結算所有限公司提交了最新的證券變動月報表，報告截至2024年3月31日的公司股份變動情況。報告顯示，新銳醫藥的法定/註冊股本及已發行股份在報告期內均無變動，維持在3,000,000,000股，每股面值0.05港元，總股本為150,000,000港元。此外，根據2013年10月25日採納的股份期權計劃，公司於報告月內無新增股份期權行使，結存的股份期權數目為143,200,000，並無因行使期權而得到的資金。公司秘書吳日升確認，所有證券發行均已獲得董事會批准，並符合香港聯合交易所有限公司證券上市規則的相關要求。
XINROI PHARMACEUTICALS INTERNATIONAL HOLDINGS LIMITED (XINROI PHARMACEUTICALS) SUBMITTED ITS LATEST SECURITIES MONTH CHANGE REPORT TO HONG KONG TRADING AND SETTLEMENT LIMITED ON APRIL 2, 2024, REPORTING THE CHANGES IN THE COMPANY'S SHARES FOR THE YEAR ENDED MARCH 31, 2024. The report shows that Novi Pharmaceuticals' regulary/registered share capital and issued shares remained unchanged during the reporting period at 3,000,000,000 shares with a face value of HK$0.05 per share and a total share capital of HK$150,000,000. In addition, under the share option plan adopted on October 25, 2013, the Company did not exercise new stock options during the reporting month, and the number of outstanding share options was 143,200,000, with no funds received as a result of the exercise of the options. Company Secretary Wu Zhisheng confirmed that all securities issues have been approved by the Board of Directors and comply with the relevant requirements of the Securities Listing Rules of the Hong Kong Stock Exchange Limited.
XINROI PHARMACEUTICALS INTERNATIONAL HOLDINGS LIMITED (XINROI PHARMACEUTICALS) SUBMITTED ITS LATEST SECURITIES MONTH CHANGE REPORT TO HONG KONG TRADING AND SETTLEMENT LIMITED ON APRIL 2, 2024, REPORTING THE CHANGES IN THE COMPANY'S SHARES FOR THE YEAR ENDED MARCH 31, 2024. The report shows that Novi Pharmaceuticals' regulary/registered share capital and issued shares remained unchanged during the reporting period at 3,000,000,000 shares with a face value of HK$0.05 per share and a total share capital of HK$150,000,000. In addition, under the share option plan adopted on October 25, 2013, the Company did not exercise new stock options during the reporting month, and the number of outstanding share options was 143,200,000, with no funds received as a result of the exercise of the options. Company Secretary Wu Zhisheng confirmed that all securities issues have been approved by the Board of Directors and comply with the relevant requirements of the Securities Listing Rules of the Hong Kong Stock Exchange Limited.
Helpful
Not Helpful

This announcement is a separate document:

Doc 1     View Translation

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more